Competing interests
AMO
A.M. received honoraria from AstraZeneca, Clovis, GSK and PharmaMar. N.C.D. declared honoraria from AstraZeneca and Merck. W.J. received honoraria from AstraZeneca and GSK. S.W. declared honoraria from GSK, Merck, AstraZeneca. H.M. is on the advisory board for AstraZeneca, Merck, Essai and GSK. J.L.E. reported speaker fees and advisory board participation for AstraZeneca, GSK and Merck. L.G. declared consulting advisory board fees from AstraZeneca, Alkermes, Merck, Eisai, Eisai-Merck, GSK. She also declared institutional grants from Astra Zeneca, Pfizer, Merck Sharp & Dohme, Kayopharm, Alkermes, ImmunoGen Inc, Roche, Mersana, Esperas, Novocure GmbH, Oncoquest Pharmaceuticals, K-Group Beta Inc. V.B. received honoraria from AstraZeneca and had an uncompensated advisory role in AstraZeneca and GSK. T.S. received honoraria from GSK, AstraZeneca, and Merck. AMO declared uncompensated consulting or advisory role in AstraZeneca and GSK. He has uncompensated relationships with AstraZeneca and Clovis and research funding from AstraZeneca, GSK and Clovis. S.L. declared consulting fees from AstraZeneca, GSK, Merck, Eisai, Novocure, Novartis, Shattuck laboratories. Stephanie Lheureux is principal investigator or co-investigator of different clinical trials with agents from AstraZeneca, Merck, Roche, GSK, Regeneron, Repare Therapeutics, Clovis. The remaining authors declare no other competing interests.